https://www.live-feeds.com/feed/roche-targets-emerging-oncology-market-with-new-lung-cancer-drugContinuously updated, source-cited coverage. https://www.live-feeds.com/feed/roche-targets-emerging-oncology-market-with-new-lung-cancer-drughttps://www.live-feeds.com/feed/roche-targets-emerging-oncology-market-with-new-lung-cancer-drug#u163649Fri, 30 Oct 2026 11:10:47 +0000Roche reports positive late-stage trial results for its lung-cancer drug divarasib, a KRAS G12C inhibitor. The study shows the treatment reduced the risk of death by 44 percent and extended patient survival by nearly six months compared to standard care. These findings position the pill favorably against competing products from Amgen and Bristol Myers Squibb within the oncology market.Why it mattersThe data were presented at the European Society for Medical Oncology congress, highlighting advancements in targeted cancer therapies. Divarasib targets specific genetic mutations in non-small cell